

A Mechanistic Study Of Mifamurtide (MTPPE) In Patients With Metastatic And/Or Recurrent Osteosarcoma

Submission date 18/09/2014	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 18/09/2014	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 11/06/2019	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/trials/a-trial-of-mifamurtide-for-advanced-osteosarcoma-memos>

Contact information

Type(s)

Scientific

Contact name

Ms Linda Collins

Contact details

Oncology Clinical Trials Office (OCTO) - Department of Oncology
Old Road Campus
Roosevelt Drive
Headington
Oxford
United Kingdom
OX3 7DQ
+44 (0)1865 227162
octo-eurosarc@oncology.ox.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT02441309

Clinical Trials Information System (CTIS)

2012-000615-84

Protocol serial number

16801

Study information

Scientific Title

A Mechanistic Study Of Mifamurtide (MTPPE) In Patients With Metastatic And/Or Recurrent Osteosarcoma

Acronym

MEMOS: a Eurosarc Study of Mifamurtide in advanced osteosarcoma

Study objectives

This is a Bayesian designed multi-arm, multi-centre open-label phase II study in patients with metastatic and/or recurrent osteosarcoma, which will investigate why some patients with osteosarcoma may respond better than others to mifamurtide given alone or in combination with ifosfamide.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South Central - Oxford C Research Ethics Committee, 13/06/2014, ref: 14/SC/0255

Primary study design

Interventional

Study design

Both; Interventional; Design type: Treatment

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Sarcoma; Disease: Bone

Interventions

Patients with relapsed or metastatic osteosarcoma will be divided into three treatment groups (Arms). Depending on their current disease status, patients may be either Registered to Arm A (resectable group), to receive Mifamurtide alone; or Randomised to Arm B/C (non-resectable group), to receive mifamurtide in combination with ifosfamide.

Arm A - Mifamurtide alone; Arm B - Ifosfamide alone for 6 weeks then Ifosfamide + mifamurtide for 6 weeks, then mifamurtide alone for 30 weeks; Arm C - Ifosfamide + mifamurtide for 12 weeks then mifamurtide alone for 24 weeks. All participants will receive 36 weeks or more of mifamurtide.

Biopsies (or resected tumour samples) will be obtained before and after 6 weeks of therapy interval in order to determine the pharmacodynamic endpoints. The target sample size is 40 patients. An interim analysis will be performed for the primary efficacy endpoint.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Mifamurtide, Ifosfamide

Primary outcome(s)

Objective Radiological response; Timepoint(s): Pre-treatment, after 6, 12, 18, 24 & 36 weeks of treatment

Key secondary outcome(s)

1. Biological response; Timepoint(s): Pre-treatment and after 6 weeks of treatment
2. Disease specific overall survival; Timepoint(s): End of trial
3. Progression free survival on serial CT scan; Timepoint(s): Pre-treatment, after 6, 12, 18, 24 and 36 weeks of treatment
4. Safety and tolerability on CTCAE Criteria (v4.0); Timepoint(s): Throughout trial treatment

Completion date

11/03/2016

Eligibility

Key inclusion criteria

1. Relapsed osteosarcoma (first, second, third or any relapse, patient has recovered from chemotherapy and any other investigational drug/agent treatment, radiotherapy or surgical procedure).
2. Histological confirmed diagnosis of osteosarcoma at original presentation.
3. Tumour at biopsy accessible or resectable site.
4. Progressive disease documented by imaging within 3 months of entry into the trial.
5. At least one measurable lesion on CT scan (RECIST) performed in past 21 days prior to trial entry.
6. Male or female, age = 16 years to 65 (or =18 based on institutional practice for Teenage and Young Adult Cancer patients).
7. Life expectancy of at least 3 months.
8. WHO performance score of 0 - 2.
9. The patient is willing and able to comply with the protocol and scheduled follow-up visits and examinations.
10. Written (signed and dated) informed consent.
11. Cardiac shortening fraction = 28% or ejection fraction = 45%
12. Renal function is adequate for ifosfamide treatment (GFR as per table below, other renal function screening tests as per local practice)
13. Haematological and biochemical indices within the ranges detailed in the protocol

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Pregnant or breastfeeding woman. Men or women of childbearing potential unless effective methods of contraception are used during study treatment and for at least 7 days after the last mifamurtide dose.
 2. Previous treatment with mifamurtide or a mifamurtide like drug* in a clinical trial setting for the treatment of metastatic and/or recurrent osteosarcoma in the six months prior to registration.
 3. Contraindications to lung biopsies
 4. Hypersensitivity to ifosfamide or any component of the formulation.
 5. Previously diagnosed brain metastases.
 6. Significant active cardiac disease including: uncontrolled high blood pressure (no greater than 2 standard deviations above the mean for age for systolic blood pressure (SBP) and diastolic blood pressure (DBP), unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias and with a history of pericarditis and myocarditis
 7. Treatment with any other investigational agent, or participation in another interventional clinical trial within 21 days prior to enrolment.
 8. Major surgery within 21 days prior first study biopsy
 9. Currently taking of high-dose nonsteroidal antiinflammatory drugs (NSAIDs) or corticosteroid treatment
 10. Concurrent use of ciclosporin or other calcineurin inhibitors.
 11. Any psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
 12. Any other active malignancy, with the exception of adequately treated conebiopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions.
 13. Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV.
- * mifamurtide-like drugs include GMCSF, interferon and other macrophage activating molecules.

Date of first enrolment

12/09/2014

Date of final enrolment

11/03/2016

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre
Oncology Clinical Trials Office (OCTO)
Oxford
United Kingdom
OX3 7DQ

Sponsor information

Organisation
University of Oxford (UK)

ROR
<https://ror.org/052gg0110>

Funder(s)

Funder type
Government

Funder Name
European Commission

Alternative Name(s)
European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location

Funder Name
Millenium Pharmaceuticals Inc. (USA)

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
HRA research summary			28/06/2023	No	No